Related references
Note: Only part of the references are listed.Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M. D. Hellmann et al.
ANNALS OF ONCOLOGY (2019)
Consequences of a high incidence of microsatellite instability and BRAF-mutated tumors: A population-based cohort of metastatic colorectal cancer patients
Kristine O. Aasebo et al.
CANCER MEDICINE (2019)
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
Cathy Eng et al.
LANCET ONCOLOGY (2019)
Immunotherapy in colorectal cancer: Available clinical evidence, challenges and novel approaches
Joseph Tintelnot et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?
Francois Ghiringhelli et al.
FRONTIERS IN IMMUNOLOGY (2019)
The Emerging Role of Checkpoint Inhibition in Microsatellite Stable Colorectal Cancer
David J. Hermel et al.
JOURNAL OF PERSONALIZED MEDICINE (2019)
Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer
James J. Lee et al.
CLINICAL COLORECTAL CANCER (2018)
The impact of microsatellite stability status in colorectal cancer
Ruby Gupta et al.
CURRENT PROBLEMS IN CANCER (2018)
TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study
Yasutoshi Kuboki et al.
LANCET ONCOLOGY (2017)
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
Michael J. Overman et al.
LANCET ONCOLOGY (2017)
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma
Bert H. O'Neil et al.
PLOS ONE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
A phase II study of pembrolizumab in combination with mFOLFOX6 for patients with advanced colorectal cancer.
Safi Shanda et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Clinical activity and immune correlates from a phase lb study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma
Jeffrey Wallin et al.
CANCER RESEARCH (2016)
Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
Christina Pfirschke et al.
IMMUNITY (2016)
Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Robert J. Mayer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
M. Koopman et al.
BRITISH JOURNAL OF CANCER (2009)
Molecular predictors of survival after adjuvant chemotherapy for colon cancer.
T Watanabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer
R Gryfe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
